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Abstract Development of the means to efficiently and
continuously renew missing and non-functional proteins in
diseased cells remains a major goal in modern molecular
medicine. While gene therapy has the potential to achieve
this, substantial obstacles must be overcome before clinical
application can be considered. A promising alternative
approach is the direct delivery of non-permeant active
biomolecules, such as oligonucleotides, peptides and pro-
teins, to the affected cells with the purpose of ameliorating
an advanced disease process. In addition to receptor-me-
diated endocytosis, cell-penetrating peptides are widely
used as vectors for rapid translocation of conjugated
molecules across cell membranes into intracellular com-
partments and the delivery of these therapeutic molecules
is generally referred to as novel prospective protein ther-
apy. As a broad coverage of the enormous amount of
published data in this field is unrewarding, this review will
provide a brief, focused overview of the technology and a
summary of recent studies of the most commonly used
protein transduction domains and their potential as thera-
peutic agents for the treatment of cellular damage and the
prevention of regulated cell death.
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Cell-penetrating peptides and their composition
The hydrophobic nature of cellular membranes and the
blood–brain barrier selectively restrict cells from taking up
exogenous molecules larger than 500 Da. This is one rea-
son why virus-mediated gene expression was considered
for a long time as the most efficient and reliable approach
for expressing bioactive proteins de novo, aiming to correct
defects of proteins involved in a plethora of different
genetic-metabolic disorders and diseases. Nevertheless,
viral vectors are capable of integrating into the host chro-
matin and this may have serious consequences from long-
term effects which limit the clinical and therapeutic
applications of virus-associated material such as aden-
oviruses, herpes viruses or lentiviruses [1]. An impressive
alternative strategy to penetrate the impermeable phos-
pholipid bilayer of cell membranes and to cross biological
barriers is derived from the HIV transactivator (Tat) pro-
tein. Following secretion from HIV-infected cells, Tat
translocates into neighboring cells to modify gene tran-
scription and spread the disease [2]. The first report that
demonstrated that a Tat-derived peptide can deliver a large
protein into different cell types and mammalian organs was
published by Fawell and colleagues in 1994 [3]. Initially,
they chemically cross-linked and identified a 36-amino
acid region of HIV-1 that was able to promote the uptake of
b-galactosidase as a chimera into living cells. This HIV Tat
protein transduction domain (PTD) contains a cluster of
basic amino acid residues and a sequence assumed to adopt
an a-helical configuration. Countless studies aimed to
delineate whether shorter domains of this Tat peptide
would be sufficient for cell internalization. The main
determinant required for translocation was identified as the
cluster of basic amino acids, while the putative a-helix
domain appeared dispensable, although peptides with an a-
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helical region can more efficiently enter cells. The research
group led by Bernard Lebleu finally identified the truncated
polycationic peptide GRKKRRQRRR that includes RNA
binding and nuclear localization signal (NLS) motifs which
was adequate for effective translocation into cells and tis-
sues [4]. At almost the same time, the group of Gilles
Divita designed, with a short peptide vector termed MPG,
the first non-covalent cell-penetrating peptide (CPP) for
delivery of nucleic acids into cultured cells [5] closely
followed by the development of Pep-1, a peptide carrier for
the cellular transfer of peptides and proteins [6]. Comple-
mentary studies suggest that at least eight positive charges
are required for efficient penetration by individual CPPs
[7]. Remarkably, too few positively charged amino acids of
the CPPs or PTDs results in poor cell adsorption and low
cellular delivery, respectively, while too many charges
leads to toxicity [8]. Nevertheless, commonly used CPPs
are passive carriers that do not initiate release of damage-
associated molecular patterns (DAMPs) or inflammatory
cytokines during the process of cytoplasmic delivery of the
cargo [9]. The aforementioned decapeptide
(GRKKRRQRRR) is the prototypic CPP whereas in gen-
eral, CPPs are relatively short peptides (normally B40
amino acids) classified into cationic, amphipathic and
hydrophobic types according to their physical–chemical
properties. CPPs are able to enter cells even across the
blood–brain barrier by passive, temperature-, energy- and
receptor-independent processes and deliver otherwise non-
permeable cargos like proteins in a bioactive, nontoxic
manner [10]. The course and dynamics result in immediate
bioavailability of the cargo. Although such routes may still
be valid for the most part, recent observations have
demonstrated that so-called Xentry (LCLRPVG), which
derived from an N-terminal region of the X-protein of the
hepatitis B virus, represents a new class of CPPs that enters
cells exclusively via an energy-dependent endocytotic
process, thereby extending the range of pathways of cel-
lular uptake [11]. Similarly, it is worth mentioning that
recent studies suggest that a receptor-mediated uptake
cannot be ruled out for any kind of CPP-conjugate [12].
Studies and exploitation of CPPs now extend into a third
exciting decade, and since the initial discovery of Tat-
mediated delivery, many other promising transduction
domains have been discovered. Meanwhile, hundreds of
sequences now fall within the cell penetrating peptide
classification. The most widely used CPPs are listed in
Table 1.
Although there seems to be little or no homology
between the primary and secondary structures of the dif-
ferent PTDs, the efficacy of cellular transduction has been
found to correlate strongly with the number of basic amino
acids. Although there is no restriction on the size or type of
the delivered cargo, the capacity for successful uptake of
cargoes into cells increases when the cationic PTD is
attached to lower molecular weight compounds [13, 14].
CPPs enter cells by various mechanisms including direct
translocation through the membrane and clathrin-indepen-
dent macropinocytosis but the exact pathway of cellular
uptake has not been entirely resolved [15]. Likewise, it is
still not clear if there is a correlation between the peptide
secondary structure and its ability to transduce into cells.
That the transduction efficacy of proteins with PTD or
CPPs, mediated by the positively charged arginine and
lysine residues within the peptide, could be abolished by
the addition of highly negatively charged molecules
strongly suggests that the transduction process occurs in a
manner dependent on the presence of sialic acid residues
present in glycosphingolipids or heparin sulfate proteo-
glycans that are expressed ubiquitously on the cell surface
[16]. However, using cells deficient in glycosaminoglycans
and sialic acids, the group of Steven Dowdy has demon-
strated that PTD-mediated induction of macropinocytosis
and cellular transduction of CPPs occurs just as efficiently
in the absence of heparin sulfate and sialic acid [17]. It has
become clear, however, that, at least for many cationic
CPPs, binding to glycosaminoglycan is a substantial step
Table 1 Commonly used cell-penetrating peptides (CPPs)
Peptide Sequence References






Poly-arginine (R8-R12) RRRRRRRR-RRRRRRRRRRRR [126]
Transportan GWTLNSAGYLLGKINLKALAALAKKIL [127]
VP22 DAATATRGRSAASRPTQRPRAPARSASRPRRPVQ [128]
a Derived from the Drosophila Antennapedia homeodomain (residues 43–58)
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before transduction into the cell, but above a concentration
threshold (generally in the low micromolar range) CPPs
can also penetrate the membrane directly [18]. In general,
the individual nonhomogeneous composition, density and
fluidity of the lipid bilayer of various cell types affect the
rate and mode of uptake of CPPs [19]. Peptides with the
correct physicochemical composition might be able to
cross the cell membrane directly and would be immediately
available in the cytosol, closely resembling the behavior of
small molecules [20]. In this context, it is worth mention-
ing that the Tat-domain alone, without any further cargo,
possesses intrinsic neuroprotective properties in vitro as
well as in vivo [21] and simple poly-arginine (up to R18)
has high neuroprotective potency in stroke models relative
to other PTDs or CPPs [22]. The cytoprotective properties
of poly-arginine, probably mediated by interfering with
NMDA signaling, highlight the need to interpret the
abundant neuroprotection studies using CPPs as delivery
agents with caution, but indicates that they are ideal carrier
molecules to deliver neuroprotective drugs to the CNS
following injury like cerebral ischemia, Parkinson’s dis-
ease or Alzheimer’s disease. In addition, remarkable is the
observation that cationic CPPs themselves (without further
cargo) are occasionally able to downregulate TNF recep-
tors at the cell surface which could inhibit TNF-mediated
signal transduction in this setting.
Final location of CPPs after cellular entry
To elucidate the exact mechanisms of cellular entry, CPPs
have been intensively studied for the last two decades. The
most proposed feasibilities of cellular delivery of cargoes
mediated by CPPs are illustrated in Fig. 1. In contrast to
thesemechanisms of cell entry for a plethora of CPPs, little is
known about the subsequent intracellular cytosolic traffick-
ing of the penetratedmolecules which is of course crucial for
the cargo to reach its intended target. Once inside the cell,
CPP-linked cargoes remain in the cytoplasm or move to
other compartments whereas specific targeting to particular
organelles requires the addition of extra ‘‘address motifs’’
within the PTD sequence. Therefore, it is possible to alter the
distribution of a cargo by modifying the CPP itself. For
example, mutation of three amino acids within the penetratin
sequence maintains it within the cytoplasm instead of its
default localization in the nucleus [23]. Furthermore, using a
variety of subcellular localization sequences, organelle-
specific directed delivery of CPPs to the endoplasmic retic-
ulum and mitochondria has been described in mammals [24,
25]. The enhancement of cell specificity using activat-
able cell-penetrating peptides (ACPPs) [26] and the
aforementioned targeted transport of cargo into specific
organelles by insertion of corresponding localization
sequences are only two promising developments for the
purpose of specific therapeutic applications of CPP-conju-
gates. ACPPs consist of a polycationic domain connected via
a linker to a neutralizing polyanionwhich reduces the overall
charge to nearly zero and thus inhibits electrostatic uptake
into cells. The linker can be cleaved by enzymes produced in
cancer cells (preferably matrix metalloproteinase-2 and -9).
This activates the cell-penetrating properties of the peptide,
allowing specific entry into cancer cells [27]. This modus
operandi may be a novel chemotherapeutic approach that
specifically targets the activity of CPP-conjugated anti-
cancer drugs to tumor tissue.
Beyond this, the nature of the link between the vector
(CPP or PTD) and the cargo is also of importance. If these
two elements are linked through a disulfide bridge, the
Fig. 1 Proposed mechanisms for cellular internalization of CPPs.
First of all, each CPP-conjugate binds to the plasma membrane via
electrostatic interactions. Subsequently, the complete conjugate is
internalized and released through various conceivable mechanisms.
Route 1 represents cell entry of the CPP-complex through the
formation of an inverted micelle (aggregates of colloidal surfactants
in which the polar groups are concentrated in the interior and the
lipophilic groups extend outward into the solvent). The majority of
CPPs probably enter cells by an endocytosis-driven pathway which is
depicted as Route 2. Route 3 is a direct, energy- and receptor-
independent penetration and transduction process of the construct
through the plasma membrane
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cargo is rapidly released through the action of cytoplasmic
glutathione. If the link is permanent, as in a fusion protein,
then the final localization of the chimeric molecules will
depend on the properties of both elements [28]. Never-
theless, the major rate-limiting step of CPP-mediated drug
delivery is the escape of the cargo from endosomes into the
cytoplasm and/or nucleus of the target cell, whereas only a
small fraction of CPPs fulfill these requirements [29].
Therefore, extensive and also individual experimentation is
required and of paramount importance to determine the
optimal CPP for any given cargo and cell type to escape
this bottleneck. The most promising efforts towards
enhancing endosomal escape without increasing cell toxi-
city take their cue from mechanisms that are used by
enveloped viruses like influenza or retro-viruses to escape
endosomes during infection [30]. To discover translocated
molecules, different methods for detecting the stability and
activity of CPPs and cargoes in relation to proteolytic
cleavage have been widely developed [31]. For instance,
the amount and proteolytic cleavage of internalized CPP-
conjugates is often studied by HPLC with fluorescent
detection and by MALDI-TOF MS analysis [32].
Another sophisticated approach used a transducible Tat-
Cre recombinase reporter assay in viable cells where the
functionality of the transduced cargo was indicated and
confirmed through the genetic reconstitution of EGFP
expression [10]. Such proceedings are extremely conve-
nient for the purpose of designated therapeutic applications
of the cargo.
Pharmacokinetic studies of the commonly used CPPs
(listed in Table 1) proved that the distribution of radiola-
beled conjugates in mammals in general showed a high
transient accumulation of the injected drugs in well-per-
fused organs and rapid clearance from circulation. All of
the tested CPPs revealed a relatively low accumulation rate
of the peptides in the brain, whereas the highest uptake
values were detected in the liver and the kidneys [33]. The
data herein support individual design of peptide-based
therapeutics, particularly for topical application.
Regulated cell death (RCD) as innovative scope
of CPP application
Retrospectively, the evidence that large Tat-domain-con-
jugated enzymes are indeed able to transduce mammalian
cells in vivo and that these proteins can be delivered with
high efficiency and preserved biological function in a
whole organism was reported for the first time in 1999 [34].
In the aftermath of this landmark paper, many manuscripts
were published on this topic, including many false-positive
artificial interpretations and reports on cells that were fixed
after treatment with dye-labeled CPPs [35]. In general, the
main difficulty consists in correctly judging whether a
substance is just bound to the cell surface or taken up into
the cell. This is a challenge, but simple western-blots are
often sufficient to definitively answer the question.
Meanwhile, there are a plethora of different variants of
CPPs and PTDs described in the literature [36]. The
number of applications using peptide carriers for the
delivery of therapeutically relevant molecules is continu-
ously increasing and so far more than 300 studies from
in vitro to in vivo have been reported [13]. From a clinical
perspective, effective delivery of recombinant proteins
might result in the therapeutic replacement of dysfunc-
tional or missing proteins. Of course, due to the
comparatively short circulating half-life in vivo, these
recombinant drugs often need to be administered fre-
quently. Uptake of functional, biologically active
recombinant proteins offers a promising opportunity to
agonize or antagonize signal transduction pathways which
are mediated by or involved in a variety of molecularly
controlled processes resulting from regulated cell death
(RCD) and culminating in tissue injury and inflammation.
RCD is a physiological process that controls homeostatic
events whose deregulation can lead to the development of a
number of human diseases and tissue damage [37].
Apoptosis is the most studied and best described form of
caspase-dependent regulated cell death, but current inves-
tigations indicate that RCD can also occur via regulated
necrotic pathways. At the moment, the Nomenclature
Committee on Cell Death has classified RCD into different
subtypes in an attempt to include all available published
data [38]. In this issue many outstanding experts in the field
present recent insights into proteins and complex signaling
mechanisms that control diverse forms of RCD including
(but not limited to) necroptosis, mitochondrial permeability
transition (MPT)-dependent regulated necrosis, parthana-
tos, ferroptosis and mitophagy. Therefore, we will refrain
from listing all these effectors and pathways in detail here,
and relegate at this point to the excellent reviews in this
collective edition (or reviewed in [39]). A trendsetting area
of CPP application includes diseases that result from RCD
processes. Clinically relevant examples of this cell death
form include disorders with acute or chronic courses like
ischemia reperfusion injuries [40, 41], brain trauma [42],
myocardial infarction [43], inflammatory diseases [44, 45],
sepsis [46], oxidative stress-related disorders [47], neu-
rodegenerative diseases [45], transplantation [48] and
cancer [49], in addition to a multiplicity of other patho-
physiological settings.
Furthermore, the technology and application of CPPs
have contributed to the detection of a completely new form
of regulated cell death which is distinct from apoptosis or
necrosis. Using Tat-Beclin 1 as a cell-penetrating, autop-
hagy-inducing synthetic peptide, the group of Beth Levine
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defined autosis, a novel autophagy-dependent form of cell
death which is inhibitable in vitro and in vivo by cardiac
glycosides [50]. Nevertheless, proof of specificity is
missing in this study; above all, the scrambled Tat-Beclin 1
used therein is not the proper control peptide. To generate
an optimal control peptide, essential amino acid residues
must be mutated while leaving the remaining peptide
sequence intact to exclude artificial effects of the pene-
trating construct. Furthermore, so far, it is unclear why Tat-
Beclin 1 promotes autophagic cell death and whether this
mode of cell death indeed represents a physiological event;
understanding both would be essential to define a new type
of RCD. Therefore, the enthusiasm of the scientific com-
munity regarding the existence of autosis as another form
of RCD has so far remained limited [51].
Synthesis of molecules that enable cellular uptake
To date, over 100 CPP-conjugated proteins with different
functions have been transported effectively into cells in
various animal models. In contrast to the fact that this
technology for intracellular delivery has been applied
worldwide for over 15 years, the number of proteins
making it to clinical trials is manageable. Definitely, there
is no lack of creative concepts. The greatest hurdle based
on our own experience is not the delivery, at least in vitro,
but the successful purification of recombinant proteins in a
biologically active form. In the last decade, we have cloned
more than 25 different fusion proteins conjugated with
diverse CPPs. All of them interact with different signal
transduction pathways involved in RCD, but approaches
with only two of them, namely Tat-FLIP and Tat-crmA, led
to exploitable findings [52, 53].
All of the different proteins could be expressed suc-
cessfully in our laboratory, sometimes only after testing
many different expression strains. However, an insuperable
obstacle is the solubility of the recombinant proteins
because most of them are preferentially enriched in bac-
terial inclusion bodies and this phenomenon is not
dependent on the molecular size or natural occurrence of
the protein in vivo. ‘‘Optimization of culture conditions’’ is
the standard term in each troubleshooting protocol to avoid
this waste of time. Of course, it is normally easy to purify a
recombinant fusion protein in great quantities and qualities
under denaturing conditions, but this does not solve the
problem. In contrast to statements in textbooks and
approved standard reports [54], we were not able to
transduce even one recombinant CPP-conjugated fusion
protein that was initially purified under denaturing condi-
tions followed by a refolding process. All proteins prepared
in such a manner precipitate in our hands sooner or later
in vitro and certainly, a fortiori, in vivo. Indeed, this is the
real malady of the technology, which limits the compre-
hensive commercialization of CPPs for clinical purposes.
Of course, we are aware that our empirical experience is in
contrast to many other approaches and primary publica-
tions in which denatured proteins may transduce more
efficiently into cells than low energetic, correctly folded
proteins, and that these denatured proteins may be correctly
refolded inside the cell by chaperones [55, 56]. Obviously,
these purification conditions sounded very promising not
least because many recombinant proteins in a variety of
expression systems lead to the formation of high level
insoluble protein aggregates but unfortunately, we have not
been able to reproduce this technology successfully in our
lab with any recombinant fusion protein.
Using affinity tags greatly simplifies the protein purifi-
cation process from crude biological extracts and thus
improves the yield of the recombinant protein. If the
downstream application warrants the use of a native pro-
tein, the tag must be cleaved after purification using a
sequence specific protease. Of course, affinity tags may
have unintended consequences, but small affinity tags like
69 His, FLAG, Strep II or CBP exert minimal effects on
the structure, activity and characteristics of a recombinant
protein and have limited interactions with other proteins
and, therefore, usually will not need to be removed [57].
Especially for in vitro assays, the inclusion or absence of
serum from the incubation medium and its influence on the
capacity of CPPs to penetrate membranes is controversial
[58]. At least with our commonly used conjugates we do
not see any substantial differences between the presence
and absence of serum. However, since most CPPs are
positively charged or hydrophobic, one would assume that
they bind to blood plasma proteins at least after intravenous
injection in vivo, which prohibits the release of the cargo in
a bioactive form after cellular uptake.
Finally, it is worth mentioning that post-translational
modifications are often required for the activity of mam-
malian proteins and for this reason not all fusion proteins
can be expressed effectively in bacteria. Currently, we
know of exactly one publication that describes the gener-
ation of eukaryotic cell lines that secrete biologically active
Tat fusion proteins into the culture supernatant [59].
Therapeutic applications of cell-penetrating
peptides in the context of RCD
Over the last decade, protein transduction with cell-pene-
trating peptides has been shown to be a highly efficient way
of delivering proteins at least in vitro. Nevertheless, the
in vivo application of CPPs appears to be much more
complex. Often, there is a gulf between the data and results
generated in a specific cell line under cell culture
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conditions and (patho-) physiological conditions in living
mammals. Nevertheless, there are countless examples of
successful applications of CPPs in treatment of human
relevant injuries in the current literature, including
decreased tumor growth and induction of cancer cell death
(reviewed in [60]). Cargo parameters like size, structure,
charge or other biophysical properties can exert a deep
influence on cellular uptake and cytosolic distribution but
the fact that there is no limitation on the size or type of the
delivered cargo opens a wide range of opportunities illus-
trated by a plethora of reports [61]. Because of the main
topic of this issue, we will focus in this chapter on some
selected in vivo applications of CPPs and cargoes that deal
with RCD, inflammation and cancer. A summary of these
approaches is shown in Table 2. We do not claim that the
following illustrations include all promising approaches in
this field. The listed examples represent a small excerpt of
the bulk of excellent in vitro studies, such as a really
intriguing approach which described for the first time the
incorporation of a CPP-conjugated Cas9 protein and CPP-
complexed guide RNAs as a novel gene editing strategy for
disrupting disease-causing genes in embryonic stem cells
and other cell types [62].
For a long time it was assumed that apoptosis was the
only regulated form of cell death. Therefore, most suc-
cessful applications of CPP-assisted delivery of proteins or
peptides dealing with RCD have been reported in the
context of apoptotic signaling pathways. Our own group
discovered that incubation of lymphocytic Jurkat or BJAB
cells with a recombinant Tat-FLIPs fusion protein signifi-
cantly inhibits Fas-induced activation of procaspase-8 and
downstream caspases, preventing cells from undergoing
apoptosis. Systemic application of this protein prolongs
survival and reduces multiorgan failure due to otherwise
lethal Fas-receptor-mediated apoptosis in vivo [52]. Given
that in clinically relevant cell death, the intrinsic and the
extrinsic apoptotic pathways often synergistically con-
tribute to organ failure, we developed Tat-crmA, a fusion
protein that is capable of blocking key caspases of both
pro-apoptotic pathways which was demonstrated in a
murine cardiac model. Therein, a single therapeutic
application of Tat-crmA reduced infarction size by 40 %
and preserved left ventricular function [53]. Protection
against ischemic brain injury and neuronal apoptosis in
mammals has also been reported with a Tat-Bcl-xL fusion
protein which is transduced very efficiently into primary
neurons [63]. Both Tat-Bcl-xL and Tat-crmA are effective
even when they were administered after the completion of
ischemia and proved that CPPs are able to cross the blood–
brain barrier in an active manner ([63] and our own
unpublished data).
A related approach showed that the conserved N-ter-
minal homology domain (BH4) of Bcl-xL alone, after
fusion to the protein transduction domain of HIV Tat,
closes voltage-dependent anion channels (VDAC) and thus
efficiently inhibits mitochondrial cell death [64]. The same
group showed in a follow-up study that the application of
Tat-BH4 inhibited X-ray induced apoptosis in the small
intestine of mice, and suppressed Fas-induced fulminant
hepatitis and heart failure after ischemia–reperfusion injury
in isolated rat organs [65]. Unfortunately, we were not able
to confirm these very interesting findings because we have
never seen a vehicle as insoluble as the BH4 domain of
Bcl-xL. The therapeutic potential of the CPP-conjugated
BH4 domain was additionally indicated in a murine model
of acute myocardial infarction which showed the
Table 2 Selected in vivo studies using CPP-conjugated drugs as therapeutic agent of RCD
Cargo Proposed target Injury model Protection Study
FLIP Caspase-8 Multiorgan failure in mice Improve survival [52]
crmA Caspases-1 and -8 Acute myocardial infarction in mice Cardioprotective [53]





Myocardial infarction in rats Protected in a combined fashion
against IRI
[67]
haFGF Brain neurons Mouse model of Alzheimer’s disease Neuroprotective (reduce amyloid
protein deposits)
[82]
Neuroglobin Cerebral neurons Middle cerebral artery occlusion in mice Reduction of infarct size [91]
Hsp70 Chaperone activity Transient focal cerebral ischemia in mice Neuroprotective in stroke [96]
NEMO NF-jB pathway Inflammatory bowel disease (IBD) in rats Ameliorates TNBS-induced colitis [97]
D-isomer of
p53





Metabolic disorder in mice Corrects gene deficiency [108]
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significant cardioprotective properties of this peptide after
a single bolus of intravenous injection [66]. With respect to
the regulation of mitochondrial membrane permeability,
this kind of regulated cell death in the model above is often
connected globally with apoptosis, but we have shown
previously that regulated necrosis may also result from a
cyclophilin D-mediated mitochondrial permeability tran-
sition, revealing that the cellular context requires a
balanced interplay between these two modes of cellular
demise [40]. Furthermore, we were able to demonstrate in
this mentioned study that combination therapies targeting
distinct regulated necrosis pathways can be beneficial in
the treatment of ischemic injury. In a similar case, it was
shown that combined use of PEP-1-superoxide dismutase 1
(SOD1) and PEP-1-catalase (CAT) fusion proteins protects
the myocardium from ischemia–reperfusion-induced injury
in rats to a significantly higher extent as each single one
CPP alone [67]. Of course, the chosen proteins SOD1 and
CAT did not really affect distinct signaling pathways, but it
is remarkable that two antioxidant enzymes cooperatively
protected an organ against IRI.
Bcl-xL and the BH4 domain of Bcl-xL, respectively, are
worthy of discussion in a further context of therapeutic
CPP application. In a previous work, we were able to show
that RIPK3-deficient mice, in contrast to C57BL/6 wild-
type mice, were significantly protected from TNFa-in-
duced and TNFa/zVAD-mediated hyperacute shock [68].
Engagement of TNF receptor 1 signals tended, depending
on cellular background and milieu, towards caspase-de-
pendent apoptosis or RIPK-dependent necroptosis. In this
context, the group of Peter Vandenabeele detected, more-
over, that pretreatment of wild-type mice with the RIPK1
kinase inhibitor necrostatin-1 provided a similar effect in
this approach [69], a phenomenon which we cannot con-
firm, independently of the commonly used TNFa
concentration [68]. Nevertheless, both approaches indicate
that RIPK1/RIPK3-mediated cellular damage by necrosis
drives mortality during TNFa-induced systemic inflam-
matory response syndrome (SIRS). Furthermore, the
Vandenabeele group proved in this setting that RIPK3
deficiency also protected against cecal ligation and punc-
ture, underscoring the clinical relevance of this protein
kinase in sepsis. Nevertheless, it is remarkable that previ-
ous animal studies explicitly described that prevention of
apoptosis and not necroptosis in animal models of
Escherichia coli-induced sepsis improves survival. In such
a study, Hotchkiss et al. proved an apoptotic signaling in
this approach by application of a Tat-conjugated Bcl-xL
fusion protein or Tat-BH4 peptide, respectively [70].
Therein, both CPPs markedly decreased lymphocyte
apoptosis in an in vivo mouse model of sepsis which
scrutinized the real mode of regulated cell death in sepsis.
The role of caspases and their inhibitors in sepsis to cause
and protect against apoptosis, inflammation, pyroptosis and
necroptosis has been summarized in [71]. Doubtless, cas-
pase inhibitors as well as caspase deficiency greatly
improve the survival and overall disease outcome in sepsis
models [72], but Cauwels et al. showed equally that co-
administration of the pan-caspase inhibitor zVAD sensi-
tized mice to TNFa induced SIRS [73]. The discrepancies
in these reports regarding the involvement of apoptosis or
necroptosis in a disease model indicate that it is necessary
to update our understanding of regulated cell death pro-
cesses, particularly given that signaling platforms like the
ripoptosome can switch modes between apoptotic and
necroptotic cell death [74].
Beside the transforming growth factor-b activated
kinase-1 (TAK1 kinase), the adaptor MyD88 (myeloid
differentiation primary response gene 88) is a suit-
able candidate which is able to mediate the decision to die
by apoptosis or necroptosis [75, 76]. MyD88 has a pivotal
role in Toll-like-receptor (TLR) and IL-1R signaling and is
involved in mediating excessive inflammation. The inhi-
bition of this unwanted response in acute and chronic
inflammatory diseases mediated by MyD88 has significant
therapeutic potential. MyD88 is composed of a death
domain and a Toll/IL-1R domain connected by an inter-
mediary domain (INT). Based on the fact that MyD88
lacking INT is not able to transmit signals to the down-
stream kinase IRAK4, the group of Roman Jerala fused a
synthetic INT peptide consisting of 21 amino acids to
different CPPs and demonstrated that the injection of these
different constructs into mice challenged by an otherwise
lethal dose of LPS significantly suppressed the production
of IL-6 and TNFa and significantly improved the survival
of the mice [77].
Oxidative stress, or rather the formation of reactive
oxygen species (ROS), plays a significant role in effecting
cellular pathogenesis which contributes to regulated cell
death in many neurological diseases such as stroke, brain
trauma, Parkinson’s diseases and Alzheimer’s diseases
[78]. Like in sepsis, the proper multi-faceted signaling
complexes contributing to this form of RCD are not unique
and sometimes controversial. Nevertheless, literature indi-
cates that necroptosis as well as apoptosis may be
responsible for cellular dysfunctions leading to different
modes of neurodegenerative diseases [45, 79]. These
findings are also in line with a study which described that
wild-type p53 can induce both apoptosis and ferroptosis
upon ROS-induced stress [80]. How exactly p53 changes
its function to elicit different forms of cell death is an
important but so far unresolved question which remains to
be elucidated. Nevertheless, by such applied research we
will better understand the level of entangled molecular
processes and pathways contributing to cell death subrou-
tines within a complex etiopathology.
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In an approach to ameliorate neurodegenerative diseases
in patients, the group of Yadong Huang described in con-
secutive studies proteins consisting of human acidic
fibroblast growth factor (haFGF) coupled to the Tat-domain
of HIV [81–83]. Delivery of therapeutics into the brain is a
major challenge because of the blood–brain and blood-
cerebrospinal fluid barriers. Many traditional drugs cannot
cross these barriers in appreciable concentrations, with less
than 1 % of most drugs reaching the central nervous system,
leading to a lack of marketable treatments for many neuro-
logical diseases such as neurodegenerative disorders,
epilepsy, stroke and malignant brain tumors [84]. In a well-
characterized mouse model of Alzheimer’s disease using the
senescence-accelerated mouse prone 8 (SAMP8) mice,
intranasally administrated CPP-conjugated acidic fibroblast
growth factor fusions proteins retained the neuroprotective
activities of the neurotrophin-like growth factor in the brain
over a period of several weeks, and, therefore may be
promising candidates for the development, differentiation
and regeneration of brain neurons and consequently treat-
ment of neurodegenerative diseases [82]. Above all, the
fusion proteins significantly reduced b-amyloid protein
deposits in the brain and thus protected the neurons from
RCD. Accessory studies pointed out that the RIPK1/RIPK3
necrosome can form such functional amyloid signaling
complexes which could be responsible for disease progres-
sion [85]. The combination of such reports highlights once
more the concept of peptide-based strategies in the context of
intervention in degenerative processes, especially with
regard to the dramatic acceleration in the discovery of new
RCD modes during the last decade [86].
Antigen-induced blockade of airway inflammation and
hyperresponsiveness in mice were evaluated in an elegant
study using a dominant negative Ras that was fused to the
Tat protein transduction domain. At the cellular level, the
CPP-carrying mutated Ras in this model inhibits the
migration and infiltration of inflammatory cells, largely
eosinophils and mononuclear cells as well as IL-4 and IL-5
production in the lung [87].
Additionally worth mentioning is an interesting study by
Rothbard and colleagues which includes a category of
molecules that normally do not require assistance for their
uptake into cells. In general, small molecules which are
used successfully for inhibition of different forms of RCD
(e.g. necrostatin-1 or ferrostatin-1), or that operate as
chemotherapeutic drugs (e.g. doxorubicin or cyclosporin
A) are per se cell-permeable and therefore need no further
vehicles for transduction into target cells. That is why the
immunosuppressive cyclosporin A would be an ideal
component for treatment of inflammatory skin disorders
mediated by dermal T lymphocytes. Unfortunately, this
drug is only locally active and ineffective topically because
of poor penetration into the skin. To overcome this hurdle,
the aforementioned group of Rothbard conjugated a hep-
tamer of arginine to cyclosporine A and demonstrated in a
compelling fashion that, in contrast to the pure cyclosporin
A, this modified drug was efficiently transported into the
epidermis and dermis of mouse and human skin and as a
result inhibited cutaneous inflammation [88]. This
approach established a novel strategy for enhancing the
delivery of poorly absorbed drugs across tissue barriers.
Since resistance to chemotherapeutic agents, including
paclitaxel, methotrexate or glucocorticoids, is a strong
predictor of poor outcome in cancer therapy, it was pro-
posed that modulation of cell death regulators might
represent a novel and promising strategy for counteracting
drug resistance in these cells [89].
Former studies performed in mice support that Tat-conju-
gated proteins can be efficiently transduced into neurons and
protect the brain from mild or moderate ischemic injury [90].
Mammalian neuroglobin (Ngb) has been suggested to be able
to protect against brain hypoxic-ischemic injury. Unfortu-
nately, such natural inhibitors which are produced in the brain
in response to acute cerebral ischemia cannot be developed for
treatment of stroke because these potentially therapeutic
proteins do not cross the blood–brain barrier. By conducting
middle cerebral artery occlusion (MCAO), Cai et al. proved
that the concomitant application of a recombinant Tat-Ngb
fusion protein in this model resulted in significantly (about
one-third) less brain infarction volume, manifested in a better
neurological outcome, if Tat-Ngb was injected intravenously
2 h before the reperfusion was initiated [91]. It is important to
note that the protection observed was negligible when the
fusion proteinwas applied at the onset of reperfusion.This last
remark illustrates a general vulnerability of many potential
drugs; their applicationmay be too latewhen a severe incident
has been diagnosed in the patient.
Unfortunately, stroke triggers a complex series of bio-
chemical mechanisms and our knowledge of the molecular
mechanisms of stroke pathophysiology is constantly
advancing. In this context, some fundamental proteins like
MAPKs (ERK, p38 and JNK) are involved in oxidative
stress pathways and inflammation, while others like cas-
pases, Bcl-2 family proteins, PARP-1, apoptosis-inducing
factor (AIF), inhibitors of apoptosis proteins (IAPs),
receptor interacting protein kinases (RIPKs) and heat-
shock protein 70 (Hsp70) are involved in RCD pathways
[92]. The damaging mechanisms of stroke may proceed
through rapid nonspecific cell lysis (passive necrosis) or by
active forms of cell demise (apoptosis or regulated necro-
sis), depending upon the severity and duration of the
ischemic insult. Therefore, selecting promising targets for
drug discovery from these various signaling cascades is
challenging. The chaperone Hsp70 is a molecule that
reduces ischemia/reperfusion injury in the brain and evi-
dence is emerging that the activation of key players of
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RCD pathways often requires chaperones and co-chaper-
one complexes [93–95]. It was shown that treatment of
transient focal cerebral ischemia in mice with a recombi-
nant Tat-Hsp70 fusion protein resulted in a significantly
smaller infarction size and in functional improvement
compared with corresponding controls [96]. Such studies
suggest that chaperones conjugated to CPP may represent
an alternative class of neuroprotective therapeutics against
stroke.
A further clue to the applicability of CPPs in the course
of RCD processes resulted from a study dealing with the
transcription factor NF-jB, a central regulator of the
immune response. It has been known for a long time that
compounds which directly inhibit the binding of NF-jB to
DNA may block inflammation and the associated tissue
damage. Briefly, NF-jB essential modulator (NEMO) is a
component of the IKK complex which participates in the
activation of the NF-jB pathway. It was shown that the
colon-targeted cell-permeable NF-jB inhibitory peptide
TALDWSWLQTE is active against experimental colitis
in vivo and indicates the therapeutic targeting of NF-jB for
treatment of inflammatory bowel disease (IBD). Tissue
permeability and colon availability of this NEMO binding
domain peptide was examined spectro-photometrically
using FITC-labeled constructs [97].
Traditionally, therapeutics that restore genes inactivated
during oncogenesis have been of superordinate interest in
basic and translational science. It has long been speculated
that direct reactivation of the endogenous tumor suppressor
p53 in cancer cells will be therapeutically beneficial. So
far, many different p53-derived peptides conjugated to
various CPPs like penetratin or Tat have been demon-
strated to restore the tumor suppressor function of p53 in
cancer cells (reviewed in [98]). The group of Steven
Dowdy demonstrated in 2004 that a retro-inverse version of
the parental p53 peptide linked to the Tat-domain of HIV
(named RI-Tatp53C) restored p53 function specifically in
cancer cells but not in normal cells [99]. Using a peritoneal
lymphoma model they demonstrated that treatment of mice
with this transducible D-isomer of p53 resulted in signifi-
cant increases in lifespan and the generation of disease-free
animals. This approach appears valuable because it was
shown previously that p53 inhibits cystine uptake and
thereby sensitizes cells to ferroptosis, an oxidative, iron-
dependent, non-apoptotic form of RCD [100]. Ferroptosis
has recently been described and implicated in several
pathological conditions including Huntington´s disease and
kidney dysfunction [41, 101]. It is an intriguing idea that
reactivation of the endogenous p53 in cancer cells using
CPPs such as RI-Tatp53C could promote the selective
removal of cancer cells through induction of ferroptosis.
However, unequivocal controls are most important for
applying the technology of CPPs. Correspondingly, the
interpretation of necrotizing pancreatitis in regard to RCD
is somewhat disputed. Some works describe that RIPK3
deficiency in mice partially protects against cerulein-in-
duced pancreatitis (CIP), indicating the involvement of
necroptotic signaling pathways in the course of this disease
[102, 103]. However, we have shown previously a deteri-
oration of pancreatic damage in this model upon addition
of the RIPK1 inhibitor Nec-1 and our recombinant Tat-
crmA fusion protein, respectively [68]. Nevertheless, it is
striking that pretreatment of rats with the penetratin domain
alone (without any further cargo) which rapidly entered the
cells of the pancreas, attenuated the severity of pancreatic
inflammation monitored by different serum parameters of
pancreatitis and associated oxidative stress [104].
In modern medicine, molecularly targeted imaging is
gaining increasing significance. CPPs long ago became
important tools for delivering and detection of fluorophores
or luminescent nanocrystals such as quantum dots [105].
Furthermore, the grading of primary tumors and metastases
is a fundamental process in cancer therapy. The extent,
evaluation and accurate identification of metastases often
requires surgical removal of all anatomically susceptible
lymph nodes for pathological examination. Using advan-
tages of ratiometric ACPPs, Savariar and coworkers
recently established an impressive, novel method of real-
time in vivo imaging of tumors [106]. The activat-
able peptides contain Cy5 as a far-red fluorescent donor
and Cy7 as near-infrared fluorescent acceptor. Cy5 is
quenched in favor of Cy7 re-emission until the intervening
linker is cut by tumor-associated matrix metallopro-
teinases, which play crucial roles in cancer invasion and
metastasis. The attack of the protease disrupts fluorescence
resonance energy transfer (FRET), increases the Cy5/Cy7
emission ratio in a time-dependent manner and triggers
tissue retention of the Cy5-labeled peptide. This ratiomet-
ric increase provides an accelerated and quantifiable metric
to identify primary tumors and metastases in liver and
lymph nodes with increased sensitivity and specificity. The
application of CPPs in oncology represents a significant
advance over existing non-ratiometric protease sensors and
sentinel lymph node detection methods, which give no
information about cancer invasion. Such developments
illustrate the manifold range of CPP applications in medi-
cine and prove that the technology of peptide delivery is
continually undergoing refinement.
Promises and pitfalls of cell-penetrating peptides
So far, a plethora of cargoes have been successfully
delivered by CPPs or PTDs into a vast number of cell types
and in over 25 clinical trials (Phase I and II) which have
been performed predominantly using Tat-PTD, 8R and
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penetratin, evaluating this technique and its application as
valuable and safe [107]. The current status of the most
promising trials of CPP-mediated therapeutics is listed in
Table 3. Transfer of highly promising basic scientific
research into clinical applications arising for instance from
a long-term study in mice (over 24 weeks) illustrated that a
gene defect of the ubiquitous enzyme purine nucleoside
phosphorylase (PNP) leading to severe T cell immunode-
ficiency and neuronal dysfunction can be corrected
effectively by a recombinant Tat-PNP fusion protein [108].
Nevertheless, despite several promising lines of preclinical
evidence, so far no PTD- or CPP-derived drug has passed
the FDA or has reached the market. Of course, the effi-
ciency of cytosolic access of these fusion protein
conjugates is insufficient and their lack of specificity hin-
ders widespread implementation in vivo and therefore
remains a major hurdle for biomedical applications. So far,
strategies to improve the specificity of CPP-conjugates
have focused mostly on tumor targeting [109]. In the near
future, cell-targeting peptides with an intrinsic cell-
penetrating activity like so-called bioportides might expand
the repertoire of strategies available to increase the selec-
tivity of this new class of biopharmaceuticals [110]. So far,
several notable cell death relevant constructs have been
considered for clinical development. In detail: delcasertib
(KAI-9803), a Tat-coupled PKCd inhibitor which did not
show a significant decrease in heart tissue damage from
artery-opening being in a Phase II clinical trial, although
the drug reduced cardiac damage in a rat model of acute
myocardial infarction [111]; and XG-102, a Tat-coupled
c-Jun N-terminal kinase (JNK) inhibitor which reduces
myocardial ischemia–reperfusion injury and infarction size
in rats [112] is currently in an ongoing Phase III clinical
trial dealing, surprisingly, with the reduction of intraocular
inflammation post-cataract surgery [113].
At this time, the most promising candidate to become
approved by the FDA may be NA-1 (Tat-NR2B9c), a
peptide disrupting the N-methyl-D-aspartate receptor-post-
synaptic density protein-95 interaction, a pro-death
signaling pathway. This drug attenuates ischemic damage
Table 3 List of selected currently ongoing clinical trials employing CPP-conjugates
Company CPP-conjugate Label Indication Outcome References
CellGate, Inc. R7-cyclosporine A PsorBan Topical treatment of
psoriasis
Phase II clinical trials terminated [88]
Revance
Therapeutics, Inc.
Tat-Botulinum toxin RT-001 Topical treatment of
facial wrinkles





PTD4-Hsp20 AZX-100 Prevention of
dermal/keloid
scarring
Phase II completed in 2012 [130]
Amgen Tat-PKCd inhibitor KAI-9803 Acute myocardial
infarction
Phase II completed in 2011 [131]





Tat-PKCe activator KAI-1455 Ischemic injury Phase I initiated [133]
Auris Medical
(Xigen)
Tat-JNK inhibitor XG-102 Inflammatory bowel
disease
Phase I completed in 2012 (Xigen
initiates enrolment in a phase III
trial for ocular inflammation)
[113]











ISS T-002 HIV vaccine
(therapeutic
immunization)











Vectocell-SN38 DTS-108 Cancer treatment Phase I [137]
NoNO Inc. Tat-NR2B9c NA-1 Ischemic brain
damage
Phase III [114]
a Penetrating phosphodiamidate morpholino oligomer for skipping dystrophin gene
b Double-stranded RNA binding domain
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in the acute phase after stroke without affecting cerebral
blood flow in the ischemic core or penumbra. A Phase II
clinical trial proved the safety and efficacy of NA-1 in
patients with iatrogenic stroke after endovascular aneurysm
repair [114]. Therefore, this trial has the potential to rev-
olutionize the treatment of a wide spectrum of human
diseases using therapeutically effective CPPs.
Reports illustrating noticeable off-target effects of CPPs
per se are interesting for scientists but detrimental for a
contemplated clinical evaluation. In such a manner, catio-
nic CPPs, like the Tat-domain, sometimes evoke side-
effects by remodeling the plasma membrane. Transduction
of Tat-GFP fusion proteins causes membrane phospholipid
rearrangement as evidenced by detection of phos-
phatidylserine (PS) on the outer surface of the cell
membrane. Remarkably, neither apoptosis nor necrosis is
induced in these cells after exposure to Tat-GFP [115].
This observation was extended by another approach,
demonstrating that CPPs are occasionally able to induce
changes in the lipid composition of the plasma membrane.
The mechanism involves the induction of acid sphin-
gomyelinase (ASMase), which converts sphingomyelin to
ceramide at the outer leaflet of the plasma membrane. The
involvement of ASMase in CPP uptake was confirmed by a
pharmacological inhibition of ASMase by imipramine and
a subsequent rescue of uptake through external addition of
sphingomyelinase, and using ASMase-deficient cells [116].
These findings could have important implications for can-
cer therapy because ceramide is the central molecule of
sphingolipid metabolism and a lipid with important second
messenger functions which mediates anti-proliferative
responses and induction of apoptosis as well as necroptosis
[117].
Concluding remarks and perspectives
Despite extensive progress in recent years resulting in
promising lines of preclinical evidence, more work is still
needed and desirable for biomedical applications of ther-
apeutically exploitable proteins. The low cell, tissue and
organ selectivity of first generation CPPs in mammals in
combination with the low protein transduction efficiency is
a tremendous drawback of this technology and the thera-
peutic application of these carriers. In addition, the in vivo
utility of CPPs may be compromised by the general
capacity of polycationic peptides to activate mast cell
secretion [118]. Moreover, the route of administration is a
meaningful concern. Oral delivery of pharmaceutical pep-
tides or proteins is still a major challenge for
pharmaceutical industries. Negligible permeability of these
drugs across the intestinal barrier and low pH conditions of
the gastrointestinal tract reduce the delivery of intact agents
to the target and add to the short half-life and low
bioavailability of CPPs. In this regard, it is worth noting
that Xentry [119], as already mentioned, represents a new
class of cell-penetrating peptides that is not able to invade
resting blood cells, which offers a therapeutic advantage
when the drug must be administrated intravenously. Fur-
thermore, nano-carrier-based delivery represents an
appropriate choice to significantly improve uptake of CPPs
and protect cargo from proteolytic degradation with the
intention of increasing the retention time of these mole-
cules in the body, leading to a reduction of treatment cost
[120]. D-amino acids which are less susceptible to protease
activity than the biologically used L-form could be con-
sidered an alternative for preparation of CPPs to increase
serum stability. Such, it was revealed that D-isomeric
Xentry was stable in serum for 4 h, much longer than the L-
isomer which became inactive within 1 h [11].
The challenge remains to find a compromise between
avoiding the premature degradation of the cargo and
obtaining a sufficiently effective drug release rate from the
CPP-conjugate after internalization. Activatable cell-pen-
etrating peptides (ACPPs) have an enhanced ability to
penetrate their target cells within primary tumors or
metastases compared to conventional CPPs due their
cleavage by disease-associated matrix metalloproteinases
and could eliminate background activity in healthy cells in
such a manner [27]. Potential side-effects from therapeutic
molecules such as toxicity and undesired immune respon-
ses must also be considered.
Without any doubt, the current door-to-balloon-time
appears to counteract the successful and effective preven-
tion of RCD in myocardial infarction. In this regard, it is
notable that organ transplantation is unavoidably associ-
ated with transient tissue hypoxia, which may cause
ischemia–reperfusion injury (IRI), inflammation and
rejection. Our own studies demonstrated that kidney
ischemia–reperfusion is a form of acute kidney injury
resulting in a cascade of cellular events prompting rapid
cellular damage and suppression of kidney function. In this
context, we have shown for the first time that necroptosis is
a key element of IRI in the kidney and therefore will likely
emerge as a promising target in solid organ transplantation
[121]. This is due to the fact that clinically feasible inter-
ference to attenuate organ injury may only be possible
in situations in which the reperfusion damage or the mode
of regulated cell death can be anticipated, such as cardiac
surgery and solid organ transplantation. It is conceivable
that CPPs could minimize the loss of functional
parenchymal cells in the graft and/or prevent release of cell
death-associated molecular patterns (CDAMPs) which
trigger innate and promote adaptive immune responses and
activate rejection pathways [122]. At present, the applica-
bility of blocking necroptosis in transplantation is obvious,
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but has not been extensively tested. Discovery and syn-
thesis of CPPs, readily penetrating cell membranes and
concentrating primarily in mitochondria, may give new
therapeutic perspectives. CPPs are now clearly established
as a meaningful advance in the field of drug delivery in
living organisms, but time will tell if this technology is also
therapeutically useable to reset pathologic signaling net-
works in regulated cell death processes like transplantation.
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